慢性粒细胞白血病的治疗进展

The therapy of chronic myeloid leukemia

慢性粒细胞白血病（CML）具有特异性的细胞遗传学改变，形成的BCR—ABL融合基因表达相对分子质量为210kD的蛋白P210。随着分子生物学等技术的飞快发展，酪氨酸激酶抑制剂（TKI）明显地改善CML患者的疗效及预后，但存在着耐药性、不能耐受性以及TKI不能清除CML干细胞等问题，故造血干细胞移植（HSCT）仍可作为一线治疗方案，但HSCT后仍面临着诸多难题。因此，需探索清除来源于Ph＋恶性肿瘤干细胞克隆的CML微小残留病灶的方法，有望获得CML永久治愈和长期无病生存。本研究就CML的治疗进展进行综述。

The chronic myeloid leukemia（CML） is characterized by a cytogenetic abnormality. The BCR - ABL fusion gene encodes protein 210. With the rapid development of molecular biology and other technologies, the treatment of CML has made great progress.However,patients for TKI resistance,which cannot be tolerated, and TKI will not eliminate CML stem cells. Despite hematopoietic stem cell transplantation（HSCT） is recommended as first - line treatment, it is still faced with many problems. Therefore, to clear CML tiny residual lesions from Ph ＋ malignantly clonsl stem ceils has become an urgent need,which is expected to be an effective method for CML patients to obtain permanent cure and long - term disease - free survival. In this paper, we review the main advances achieved in the treatment of CML.